First-in-human study to assess the safety, pharmacokinetics and pharmacodynamics of BMS-962212, a direct, reversible, small molecule factor XIa inhibitor in non-Japanese and Japanese healthy subjects.
Perera V, Luettgen JM, Wang Z, Frost CE, Yones C, Russo C, Lee J, Zhao Y, LaCreta FP, Ma X, Knabb RM, Seiffert D, DeSouza M, Mugnier P, Cirincione B, Ueno T, Frost RJA.
Perera V, et al. Among authors: yones c.
Br J Clin Pharmacol. 2018 May;84(5):876-887. doi: 10.1111/bcp.13520. Epub 2018 Mar 5.
Br J Clin Pharmacol. 2018.
PMID: 29346838
Free PMC article.
Clinical Trial.
Exposure-dependent changes were observed in the PD parameters, activated partial thromboplastin time (aPTT) and factor XI clotting activity (FXI:C). The maximum mean aPTT and FXI:C change from baseline at 20 mg h(-1) in part B was 92% and 90%, respectively. No diffe …
Exposure-dependent changes were observed in the PD parameters, activated partial thromboplastin time (aPTT) and factor XI clotting activity …